Multigene panel analysis identified germline mutations of dna repair genes in breast and ovarian cancer

Molecular Genetics and Genomic Medicine

Volumn 3, Issue 5, 2015, Pages 459-466

  Hirotsu, Yosuke ^a   Nakagomi, Hiroshi ^a   Sakamoto, Ikuko ^a   Amemiya, Kenji ^a   Oyama, Toshio ^a   Mochizuki, Hitoshi ^a   Omata, Masao ^a,b  

^a Yamanashi Prefectural Central Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Breast and ovarian cancer; DNA repair; Gene panel; Next generation sequencing

Indexed keywords

EID: 84976246297     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.157     Document Type: Article

References (34)

1. Abecasis, G. R., A. Auton, L. D. Brooks, M. A. DePristo, R. M. Durbin, R. E. Handsaker, et al. 2012. An integrated map of genetic variation from 1,092 human genomes. Nature 491:56–65.
2. Al-Tassan, N., N. H. Chmiel, J. Maynard, N. Fleming, A. L. Livingston, G. T. Williams, et al. 2002. Inherited variants of MYH associated with somatic G:C→T: a mutations in colorectal tumors. Nat. Genet. 30:227–232.
3. Bartkova, J., J. Tommiska, L. Oplustilova, K. Aaltonen, A. Tamminen, T. Heikkinen, et al. 2008. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol. Oncol. 2:296–316.
4. Berg, K. D., C. L. Glaser, R. E. Thompson, S. R. Hamilton, C. A. Griffin, and J. R. Eshleman. 2000. Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction. J. Mol. Diagn. 2:20–28.
5. Bonai, B., S. Grandjouan, L. Huiart, O. Caron, C. Colas, and C. Bonai. 2011. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304–2310.
6. Broeks, A., J. H. M. Urbanus, A. N. Floore, E. C. Dahler, J. G. M. Klijn, E. J. T. Rutgers, et al. 2000. ATM-heterozygous germline mutations contribute to breast cancer – susceptibility. Am. J. Hum. Genet. 66:494–500.
7. Couch, F. J., S. N. Hart, P. Sharma, A. E. Toland, X. Wang, P. Miron, et al. 2014a. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J. Clin. Oncol. 33:304–311.
8. Couch, F. J., K. L. Nathanson, and K. Offit. 2014b. Two decades after BRCA: setting care and prevention. Science 343:1466–1471.
9. Cybulski, C., J. Lubiñnski, D. Wokołorczyk, W. Kuñzniak, A. Kashyap, V. Sopik, et al. 2014. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clin. Genet. 1:1–5.
10. Domchek, S. M., A. Bradbury, J. E. Garber, K. Offit, M. E. Robson, W. Cornell, et al. 2013. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net ? J. Clin. Oncol. 31:1267–1270.
11. Easton, D. F., D. T. Bishop, D. Ford, G. P. Crockford; Breast Cancer Linkage Consortium. 1993. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families consortium. Am. J. Hum. Genet. 52:678–701.
12. Economopoulou, P., G. Dimitriadis, and A Psyrri. 2015. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat. Rev. 41:1–8.
13. Grant, R. C., I. Selander, A. A. Connor, S. Selvarajah, A. Borgida, L. Briollais, et al. 2014. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148:556–564.
14. Hegde, M., M. Ferber, R. Mao, W. Samowitz, and A. Ganguly. 2013. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet. Med. 16:101–116.
15. Hirotsu, Y., H. Nakagomi, I. Sakamoto, K. Amemiya, H. Mochizuki, and M. Omata. 2014. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol. Genet. Genomic Med. 3:121–129.
16. King, M., J. H. Marks, J. B. Mandell, M. Ben-yishay, J. P. Dutcher, S. J. Gross, et al. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–647.
17. Kurian, A. W., E. E. Hare, M. A. Mills, K. E. Kingham, L. McPherson, A. S. Whittemore, et al. 2014. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J. Clin. Oncol. 32:2001–2009.
18. LaDuca, H., A. J. Stuenkel, J. S. Dolinsky, S. Keiles, S. Tandy, T. Pesaran, et al. 2014. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet. Med. 16:830–837.
19. Landrum, J. E., J. M. Lee, G. R. Riley, W. Jang, W. S. Rubinstein, D. M. Church, et al. 2014. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42:D980–D985.
20. Ledermann, J., P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, et al. 2014. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:852–861.
21. Lee, J.-H., and T. T. Paull. 2005. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308:551–554.
22. Munsell, M. F., P. T. Soliman, M. B. Clark, M. S. Daniels, K. G. White, S. G. Boyd-rogers, et al. 2006. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 354:261–269.
23. Narod, S. A., D. Ford, P. Devilee, R. B. Barkardottir, H. T. Lynch, S. A. Smith, et al. 1995. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am. J. Hum. Genet. 59:254–264.
24. Rebbeck, T. R., N. D. Kauff, and S. M. Domchek. 2009. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 101:80–87.
25. Roberts, N. J., Y. Jiao, J. Yu, L. Kopelovich, G. M. Petersen, M. L. Bondy, et al. 2012. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2:41–46.
26. Savitsky, K., A. Bar-shira, S. Gilad, G. Rotman, Y. Ziv, L. Vanagaite, et al. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749– 1753.
27. Stewart, G. S., R. S. Maser, T. Stankovic, D. A. Bressan, M. I. Kaplan, N. G. Jaspers, et al. 1999. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99:577–587.
28. Thompson, D., S. Duedal, J. Kirner, L. McGuffog, J. Last, A. Reiman, et al. 2005. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl. Cancer Inst. 97:813–822.
29. Tung, N., C. Battelli, B. Allen, R. Kaldate, S. Bhatnagar, K. Bowles, et al. 2015. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25–33.
30. Vierkoetter, K. R., A. R. Ayabe, M. VanDrunen, H. J. Ahn, D. M. Shimizu, and K. Y. Terada. 2014. Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol. Oncol. 135:81–84.
31. Vilar, E., C. M. Bartnik, S. L. Stenzel, L. Raskin, J. Ahn, V. Moreno, et al. 2011. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 71:2632–2642.
32. Walsh, T., S. Casadei, M. K. Lee, C. C. Pennil, A. S. Nord, A. M. Thornton, et al. 2011. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. USA 108:18032–18037.
33. Williamson, C. T., H. Muzik, A. G. Turhan, A. Zamño, M. J. O’Connor, D. G. Bebb, et al. 2010. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 9:347–357.
34. Yorczyk, A., L. S. Robinson, and T. S. Ross. 2014. Use of panel tests in place of single gene tests in the cancer genetics clinic. Clin. Genet. doi: 10.1111/cge.12488.